<SEC-DOCUMENT>0001193125-12-324403.txt : 20120731
<SEC-HEADER>0001193125-12-324403.hdr.sgml : 20120731
<ACCEPTANCE-DATETIME>20120731083100
ACCESSION NUMBER:		0001193125-12-324403
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120730
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120731
DATE AS OF CHANGE:		20120731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		12995343

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d388385d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) July&nbsp;30, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. Pharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective as of July&nbsp;30, 2012, the Board of Directors (the &#147;Board&#148;) of A.P. Pharma, Inc. (the
&#147;Company&#148;) appointed Robert Rosen as a director. In connection with his appointment to the Board, Mr.&nbsp;Rosen was granted options to purchase a total of up to 1,500,000 shares of Company common stock under the Company&#146;s 2007 Equity
Incentive Plan, which options vest and become exercisable with respect to 500,000 shares over one year from the date of grant and with respect to 1,000,000 shares over three years from the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Rosen is managing partner of Scotia Nordic LLC (&#147;Scotia Nordic&#148;). From 2005 to 2011, he served as global head of
oncology at Bayer HealthCare, where he was responsible for the development of the oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific. During his tenure at Bayer HealthCare, he led the launch of Nexavar for
the treatment of renal cell carcinoma and hepatocellular carcinoma. He also led premarket activities for regorafenib for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer. From 2002 to 2005, Mr.&nbsp;Rosen was vice
president of the oncology business unit at Sanofi-Synth&egrave;labo, where he was responsible for the development of Sanofi&#146;s U.S. oncology business and the launch of Eloxatin for colon cancer. Mr.&nbsp;Rosen received a Bachelor of Science
degree in Pharmacy from Northeastern University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Rosen&#146;s appointment as a director was made in connection with
the closing of the Offering (defined below), pursuant to which the Company had agreed to appoint to the Board a nominee designated by Standard Pacific Capital Holdings LLLP (&#147;SPCH&#148;); SPCH acted as the lead investor in the Offering. Scotia
Nordic served as an advisor for SPCH in connection with its participation in the Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also effective as of July&nbsp;30,
2012, Paul Goddard, Ph.D. and Gregory Turnbull resigned from the Board; Dr.&nbsp;Goddard had served as the Chairman of the Board until his resignation. In connection with their departures, Dr.&nbsp;Goddard and Mr.&nbsp;Turnbull will receive their
pro rated board compensation through July&nbsp;30, 2012, and, in recognition of their service on the Board, all outstanding unvested stock options held by Dr.&nbsp;Goddard and Mr.&nbsp;Turnbull will accelerate and all options will remain exercisable
for a period of 30 months. The resignations of Dr.&nbsp;Goddard and Mr.&nbsp;Turnbull were not caused by a disagreement with the Company. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
July&nbsp;30, 2012, the Company completed its previously announced offering of common stock in connection with that certain Securities Purchase Agreement dated July&nbsp;25, 2012, pursuant to which the Company offered and sold a total of 102,000,000
shares of common stock at a price of $0.525 per share (the &#147;Offering&#148;). Additional details regarding the Offering can be found in the Company&#146;s Current Report on Form 8-K filed July&nbsp;25, 2012. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:76pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Document Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on July 31, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: July&nbsp;31, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d388385dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%">


<IMG SRC="g388385g27g25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Appoints Robert Rosen to Its Board of Directors </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; July 31,
2012 &#150; A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Robert Rosen to its board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are delighted that Robert has chosen to join the A.P. Pharma board,&#148; stated Kevin C. Tang, A.P. Pharma&#146;s chairman of the board. &#147;Robert&#146;s particular expertise in
commercializing oncology drugs will be instrumental as we enter the commercialization phase with our lead product, APF530, for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Rosen is managing partner of Scotia Nordic LLC. From 2005 to 2011, he served as global head of oncology at Bayer HealthCare, where he was responsible
for the development of the oncology business unit for regions that included the Americas, Europe, Japan, and Asia Pacific. During his tenure at Bayer HealthCare, he led the launch of Nexavar for the treatment of renal cell carcinoma and
hepatocellular carcinoma. Nexavar&#146;s worldwide sales in 2011 were $1.0 billion. He also led premarket activities for regorafenib for gastrointestinal stromal tumors and colon cancer and alpharadin for prostate cancer. From 2002 to 2005, Mr.
Rosen was vice president of the oncology business unit at Sanofi-Synth&egrave;labo, where he was responsible for the development of Sanofi&#146;s U.S. oncology business and the launch of Eloxatin for colon cancer. Eloxatin U.S. sales in 2005, its
third full year on the market, were $1.1 billion, ranking it among the industry&#146;s most successful oncology drug launches. Mr. Rosen received a Bachelor of Science degree in Pharmacy from Northeastern University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Unfortunately, chemotherapy-induced nausea and vomiting remains a debilitating side effect that can limit the effectiveness of cancer
treatment,&#148; stated Mr. Rosen. &#147;I look forward to working with the A.P. Pharma team to help bring APF530, a promising therapeutic option for this condition, to patients worldwide.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma also announced that it has appointed Kevin C. Tang as chairman of the board, and that Paul Goddard, Ph.D. and Gregory Turnbull have resigned
from the board. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more -
</I></FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I>A.P. Pharma Appoints Robert Rosen to Its Board of Directors</I><B><I></I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Page<B> </B>
2<B></B>
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects
of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet
medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company&#146;s proprietary
Biochronomer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> drug delivery system, which allows therapeutic drug levels to be maintained for five days with a
single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV, whereas currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was
selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P.
Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of
injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company&#146;s lead product, APF530, is being developed for the
prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma received a Complete Response Letter to its APF530 New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug
Administration in September 2012. For further information, please visit the Company&#146;s web site at <U>www.appharma.com</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news
release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential
approval of APF530 and the potential timing for such approval, if approved at all, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, launch and
acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date.
We do not intend to update them except as required by law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I>A.P. Pharma Appoints Robert Rosen to Its Board of Directors</I><B><I></I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Page<B> </B>
3<B></B>
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 646-597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email:
<U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g388385g27g25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g388385g27g25.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*`!^`P$1``(1`0,1`?_$`*,```$#!0$!````````
M``````@`!`H!`P4&!PD"`0``!P$!`0```````````````@,%!@<(`00)$```
M!@(!`P,"!`0&`P`````!`@,$!08'"!$`$@DA,1-!%%%A(A9Q@9$C\+$D%1<*
M,D(S$0`"`0,#`P($!`0$!P$````!`@,1!`4`$@8A,0=!$U%A(@AQ@3(4D4)#
M%:&Q8C/!\5*"(R06%__:``P#`0`"$0,1`#\`G[\\=#0TV<OFC)LY>O7*#-FS
M06=.W;M5-LV:M6Z9E5W+E=8Q$D$$4B"8YSB!2E`1$0#KH5V8(BLSD@``5))[
M`#U.B22Q1`M(RJB@EB30*!W)/8`?/7@#N?Y[<)X;DI2B:SP37/UX8G79/+FM
M(+1F(H-^B<R2A6TFT(:6O*C=0!`P1_PL3B'!7@CR`::\>_;#RCE<,64Y/*<9
MA9*,$*UG=>X.W^0'TKU^6LG>2ONQXMQ.:7$\3B_NF73H7W;8%;J"*]W(Z'I0
M?,ZCPYH\KN_6<GKH\]L!9*;".A.4*KBD$<=0;9`QQ,5N56#*6Q/B%*(%[G<@
MX./'O]>M8\?\`^,^/JFW'BXG3^I.WN,Q^-#]('P%.FL9\G^XGRER6X=I<I-:
MVK@?^*W`C1:#TI1B?B:]>^AEB]H=EX%^TF8?8/-3"48K`NS>HY2NWS-EB\@"
MI/DFU""/K_[%,`_4.IY/P'@MS;O:3XC'/$RT_P!E5(_[E`.H%;^2N=6EVL]K
MF,E[B&H)F=NO?LQIJ2CX>O+3E3-.2XW579V9;W*Q6&+DG6*\J*MF4;/RDI!L
M5))]3+BDR1;,)5VZB&R[AC()II+G.W.BL50QTU`Q?Y^\$XOB.,?F/$(_;QT9
M7]Q;@DJ#(=JNA:II4?4I/3OK<?VZ_<+F>5YA.$<S?WLC-N_;W%`&.Q2Y24#H
M20#1OP&I-A1+VE]1]O3GW]OSZR/VUMOJ1NI_#5#*$+[CQ[C_`$#D??\``.B[
MAO\`;Z[J5_QIHM16AZ?\JZLMWK1V45&KA!RF41**K=5-=,#![E$Z1CE`P<^W
MOTHRLGZQM_'IHJ21R+O1@R?$$'_+3CN#\_Q]O3I(.I^7XZ/_`#;?75.\OOZC
MS^`<_P"770ZM^DUT!4^AU7N#\_\`'T_CUW<OQ&A4'^.EWEY`/Q^OTZ%0>H[:
MYN'YZ0&`>?IP/'KZ>OY=&((T-RFM#VTA.4!`!'U'VZX*D$T/37"RJ0K$`G2[
M@_'Z\?SYXX_J/1!(I!;T&C4ZT]=8Z7DV$-'OI:6?M(N*BV+N1DY.0<(LX^-8
M,4#N7C]\\7,1!JT:-DS***',!"$*)A$`#I1(Y)9!#""UP_TJHZEB30``=2:_
M#KI*>:.")II6"0J"6<D`*H%223VZ>O;46[<K8C/_`).H^ZTK6N\8SP9HU2K=
M^QK;G7,&48W%,1FRYHMA=DA"+N5%)US4BI'!=M&I-NU\0R;AT<`%-`NP/'O%
M>)>'+FWON=VEUE.?SP"6.TAA><VT1%0[+14#UK4[NG8>I.(?('+N:>:+>]L>
M#7EIB/&]G-[4MY<S"!;F6O558;F*D$4`6A]23T$?S:?5++FGN2FV+LOM:_\`
M[I)5F-N%9FZC-DL-4L]4E%W;1E,0,F#9DL9L+IBJF8BR"*A#%Y[1*8AC;!X%
MSSC_`)"PK9CCQG$$4C12),H21)$"LR[06`H&4@`TZZQAY"\=Y_QOG%PN?]@S
M2Q+-&\+[XY(W+!75Z`FI4]2`>G:G76PZF:69HW.FLB0F'?VHBOC*EA=[$ZN,
MZI7HL[%1V=FSC6<E]D\9IRS]9%04P<B@V*1(YU%2%*(]>+GWDOCOC>VM+OD:
MW6R]F]J(11B1BW0$E=RF@J*D5/P&O?X]\6<B\E27L/'FM=]A![LONR%!MZ_I
M.Q@3T]=H]:TKKK&<?&GG7!V!$MD5+KA#+&,6,K'P%VD,*9&;9`-CR;D%D&:+
M*R.F+)**<?%)/$6KA1FX7!!=5/N#XS@IU'^,>;N(<HY.G$HH,E99:1"T?[N`
M0K(%[[:NS]:&E4%=23E?@CE7%.)GF$D^-O<8DBQN;2<S-&S=@X"!13LU&-#3
MXZ^O%'79JS^0W5=G!)++*Q>0EK-)*(\_Z>$K5;GI2665$/9$&J`IF^G*@!]0
MZ2\^9"W@\49B-RNR2%4!/8R%@$"_$UT3[=+2XN_,6&]D-[L-P7:@[(J-N)I\
MOXZE.WGS-81K-PS;0:;@W9;,%HP59Y>MVO\`XTH#2P5\4*^\D6$_9#V!I,+M
M82O1;J+4)\C\C=981Y33$A5#$P_8>!>476,QN4N[_$V=KE(%DA]^?VV.X`A"
MI2NXUI05%>E=?0#*?</Q2TR>2QF-QN8O[S&3F.;V(`ZU4L"RL'/T?234@&G6
MFNNS._6*\P>.?->X.*74LT@H7%^2FH1U@;H,)^N7V,B'$.WK\H@W=.VOWJ<W
M(M!2.@LHDX273.F80.'3#'XWS/'_`"G8<&SR*;][RW!*'<C1.P<LIHI(V@@]
M!0@TJ!74A?RCA>0>),AS_#&1+5+.>@<`.DH3:%(!(KN9:=>M?3MKQW\>OD<Q
MAHQIMA&JW7"^Q=C@+K>+&_OF;&E-,SQE&6NV3KLS:*AK'97[(UW?157C&ZK@
MC`1)PDJ5(RIR&#J[_)7B',>0/(64FPEYBDDMH0L=I[R^X4C4#<45?HJ>@J3U
M[]]9\\6>;,3X_P#'6+AS]EE9H+F[?W;WVR(5,CD@"1C5R!W&T=C0Z][]I=QZ
MQK/&4!NCC'+^:+WEAX\C\;8\P]2WUBE[$Y8,V[]VH\E3_;0<`U09N2J"+E<%
MC$[CE2,1-4Q,X<1X3?\`+#=/)<65C:6(K/+<RA$2IH`!1F<D]MH(]*ZU)S7R
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M<J(2?=E>4`HD<=*GN-Q.T#N*BNHMQ+[@<!S3/KQO#V%Z]_\`NWAD8&L<21D[
MY)'Z`"@.T`-4]"0=<L?><FI2,!ERQ8TU'V)R9$X8LTS'7"QPJ,,E18NIPCL[
M52[3-Q3+(,H=L_.D)T&1TE'7V_\`>5!-,0-T]V_V[WXNK&URN:Q=E-D(HV@B
M.XSL\HJJB+:/P)W=/@=,4_W,V#07]QA<#E+VWQLLBSS*5]A4B-&;W17\0-O7
MXZMWKSJ42OXSI>:*SJ?L;:,/3SJ$B;1DZ3BXRH4^MVR2!07].@YB0!ZVN\S$
M_;+E%5J*#%=1(2$7[^0*KCOMQRUQG;OC5UF<7;Y^!798`S.[HA`WN`M8@:@C
M]1IW`T6]^YW$0X6VY%:8/+2X*>1$>>142)68$[$;<WN$4(_E%1KT4V1V^#!5
M+QA-U#!^9<^V_,BZ#3'5&Q=6U'*[I9:&1GA4MED=D&#IK1.,5$XJ.C&,;XU.
MPI@3.8M4\7X4>17EW:WN0LK"QL@6EGG?:`%;;1%'U2,3V`'7IZG5O\LYZW&\
M797V.QE]E+W(;1%#`E2"RAZN_78`#U-#Z^@KH2\:>46]9(A=DJZUTPRM%;&Z
MXN\8MI77UU<*PXE;2;)UVAJHP)%VE%B2/CW$4TDS2*X+MS('9I@8BW!A,2=Y
M?PY9XBZQ-W+F[1N*9:*X=+X1-1!;Q/(P,5:FI38.M:L.G35>X;S;D\Q;9FPC
MXY=)S##M;![(S`^X;F9(E`DVT#*&,A^DK12*]>@2_P#8'W9DJ/4ZUI[0)19A
M)Y&A/WEF=['J]KU#'R3Q="OTSO1/WI%N$E'N%WI/03L694S?VW!NK,^UGQS!
MF\G)SW)QJ]C92&.#>#03!2S2CI1C&`%`/2K=>PU6'W;>3;C#6,/CW#R!+Z]C
M$EP0U#[3-M6(_`,:LQ]0%IH6:KX[*O@2+UBHSC3Z^;PYEV$K]>R%<+)-6*V5
MK5["$-8%XUF[;/B4\&C2=GH&'?JG66DGZ(+H$Y1#M6*CU*,OY<R?+9\YDO[_
M`&W'<'BS-#%&L4;W]VZK6AW@D)(:@;.QJ#V.HO@_#^+X=:83'S8*[Y+G<HD4
M\DAFDCL+1&([",KN=10G>:$&HK76G>3S">7MT_(7D_%NNU7B9R'U+P+CZ`DV
MBT]"U:%J]<CV'[ADO]9-O&C83M7-K*W*@4QU/C:FX`0(/#SX2Y1@/&_BJSY#
MRR=TDSV0F:W`1F=R2D=2%'0$K6II2M/AJ/\`G?BF?\G>5KW"<0A22#!8Z%)1
MN5%C1%:2E20#3W"H`ZU%*:6@.'<J*>*/?^\8BHT_?,C9PFX##=6AJHW![//J
MG`I12=Q=Q#5,Y'<@1".N\B8Z2'>J8$!$I#"40Z3\N\CP\GG'C6,Y#=I!A["'
MWY2]1&C2!FB8GK0[E3]5*:+X=XOG(O!'*,GQ^UEFR^2D6WA]O_<V1D>\`*@L
M`"?TU)[^AUG:1K]E;`_C>D-/)VO%B]KO(KG2!2QUA"<D&45.UJB5$L"^D+3;
MFRAS)UA$[.H*BJ=P"8D^Y0(;^XFH0B&;YE@.7>9$\BVK&3@G%K(K/>!6*2N2
MU$C(4;WW.%4#N%Z5!%?=B>'\BXIX6_\`SR\4KSOE&10P6C,HDC1=H+RAFK&K
M!=Q)[5ZTH0##\4&@=XT;9;)[5[,PL7"7&@5*W5BEQ;:1;RS-A5ZQ$ELMYMK2
M41*5LNC/.8Q"/;*$X_M-'`_^*H",!\X^5,9Y0?$<0X<[OB;B=9)C3;625PL2
M;>_T=V!'<K3UU/O`OB'*>)X<QS;F<:1Y6VMY(XA7=18U+O(&'TD/4*IJ?6M.
MFAV\;F^&M.L.D>SU]R'D2)<;)99R9D"YEQ21J_<W.T2\_"-VE$9MVGV?Q/8R
M0EWCI=9R"@H-R*J`<04#L-*?+WC/FW*_(.%L<=8,O$[&SMX?W`*^S'MH\QD(
M:J.*'HP![:C?AGRAPSA_CO-Y3(7@;EV0O9Y1;48S2,1LB"5%&6K5J#0=?CK6
MLGX\R%JGX/J1AJWLEJ]EC<'8*"?JU)X06\LPC;3(,[)'0[QF?M40D3Q%*C#+
MMQ*!T5'GQ'`#E$`]^)SMAS?[C;OE5BJS8+C^,<EQ2A]A&3<I[-5F.T@]0`1T
MUY,YA<GPG[<+3C-^'BY!R'*1L(Z$$"4HY5QW6BJ-PIT)H=&-Y-Z3'JG\4'CR
M@S(IM)W)%")/1B()@0U8QK&5JG*NE4`.0PIG;2LFL(\<"9$P\^@]5MX@ND$'
M-O*%R65H+*80NX)/NSLQ50/4BB_A7X'5B>9<<LJ<'\5V0"K-?0-+$M=ABB"J
MQ)`Z=3)0_&IUB]G]_)N[[H9LUEMNVDAHCK[KW$1[=],TFO(O<UYNM:C:+<+0
MU,E7,5,.HE(22/#-&/;&6703*<`6^4?A6XAXQCLO'-AS+'8<<CY+E932.22E
MO9*&(K(H9?<K2I#&G4CIZH<T\I3WWD>_X9D,X_&>+XN*A>.,M<7KT%51RA]N
ME?I*D=J]:].`^.ZX(8UTU\K&[Z]@M,^YL+VV4ZDW3($P>5NLR6!KTDG6GEGF
MEQ(L\L+R7R#&E<B/8/W"0E`"@``$M\LQMEO(/"_&R):HD$44LL,482")F=6E
M`[_3M1Z#X=]0WQ#,N(\><W\D/+=3S7'NPP33.6GD3:RQ%BU*ON=34>HH-'/H
MK'1&G7A8D\Q':M(RS3>%\GYHF)@$$&\A)3=D2FTZ#]X]^(J[LJ;`T6DW^0QN
MPIN"\`/5;^2[FYYY]P2X,D"S%_;V:D-546+8K,`3M`-"13\QJU/&L$'`?MUD
MY(D2F^EQUQ=O1:2.T@;8K&FXD?36OY:`H5%=;O\`KS-Q%Q]K:]J+21-,XF*1
MY)ER/>?T%+P4#N%'F/*9^8B140]AZL@LG)ONI#;U3&82+HXKL_\`6C'>O3];
M&E/Q&JM,4_#OM49%7=D\[/4K3ZBL\G4"G7HB=?QIZZ[)OUCD(3"'B*\=\8H*
M3Z\7G&)K;%H@!#+LJG$P$9873E'CDQ#RMTD7`_I'U1,8?4!Z8/&V5_<\HYSY
M3O&VS6UG<"-NY9I9"(QUH"`$4$`_S"FI%Y6Q,MOQ/@GB^QC,D=S<P-*JC^6)
M$+]!U_J.U2/Y376:V]W<=3N\>1M4LF[*Y'TQUPPQ3X@S4F&J[+#F7/5K?Q4`
M]0KU=L,5!STG%Q[EK,G28I-$"$73:&#DZJG*27!O'UO;>-+/G6'Q=IG.69.Z
MD%+IU_;V2JS5>2)G4.3WJW8D$#I0J\_\CO<^1+O@6:RU[Q[AN*MH]O[5&-Q>
MM1/I21%9D'I0="%->]0$&L3*"::<^3'9US+YD+39W8_6:A1=A_>DT&=SX]K&
MR6-Y:5YM_P`P2XY,-7[4W;_-WB?[]/XO;DO5C\PFDF\B<0X8B8LW4&'OW9`B
M_LA</87!"F/]`3>!T^-#JL>%10P^/.9\W>?+_L9\EC8ED+-^]]B._@K(LGZB
MVQNI'8`Z"+RX66=LOD7V@6GA4%2%M\+5HI)4!$J$!!4FM-8I)(IP]$%FZ@K<
M!Z"*QA^O5L_;U8VUGXDQ!A4"-Q)(P%.KLYW[OCV'Y:J+[C<A<77F/,"]+.L<
MB(H/2BJBA*>O2A/YZ&(NV&T!:O5Z038C-*=/I*D8O4JTCD:TH1%?<09TU()6
M.:HR28$_V51(HM2F$Q4.T/C`O`=3(>-N!')W&4EQ-BUU<`AB8E)(;]5:@UJ>
MYU`3Y+YZV/AQ9RU^MC;E?;1964*%[`4/\-:PVSMF]I.7BT,<OY)8V;)S8&61
M;`TNM@:2]\:`@=L9K;Y%O((NK`W.V5,GV.C*E[#"''`CTY__`"7$9+>UQ=SC
M[5K"RJT"^V"(FK4%*]%-1Z#36G,N30W=SD(K^\6[N5(G82-NE#5!#D=6%/0U
MT<MNW?K]:T+U4UEP#.Y-H.4,49'M>5LJ7>..K4"&M$H-D&*+4+##SAI9ZU;)
MV0R2IU$VY#$;D`0$!XZJ?%>,<CD_)V:YES&VM+G#W=J+>W@>C`1@*"TJL.E-
MM58'U-*#5SY?R]C\;XHP?#.$SW4&<MKII[B1:H=[$D!'!]=QJ"#V&C:\8OCN
MV+VVRQ7MP-E;WEF`Q_%.6\M!6J9MMG996S$NW3530:05A7?EL<#CLS=91)T^
M342%ZB<[=H`$.HN2M_-7EKB'!\+)XVX/;V374R@2I&J&VA8BH;:`=\P%.I-%
M/4BO35E>#/$/,N>YV/R+S:YOX+"%MT<CNXN)P#U0,QJL5:BM.JD[3UKJ3=NE
MB;)6:-4,T87P^\K\5><C4I6CPLA9I%]&P;*-F'31E.'>OV3"6?$']MF<II]J
M*@F4,4!XY$>L;<&S.(P',K'.9I'EL;:Y$SJ@^IBO4`5Z5W@'Y#6X?(N"RG(.
M$7_'\`\4=W=VWLHTC$*@:@8D]2?IZ#YFNM'U7T;Q)A3"6O=5N.-,4VS*^'\?
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M5F$;D=B5K0T^===FQUE/<1W<T,+WD-?:D9%,B`]PK$5%?E36%D,.XIEK<AD"
M5QIC^3OK9%%NWNTA3*Z]MJ"#8O8V22L3J.6EDRMR?I3X5#L+Z%X#TZ]<>8S,
M%B<;:W=S%8'^FDKK'\_I#!?\->2YX_@[R_\`[G<V5I)D*4]QX49^G^HBNGZ.
M,L?-H!]5&M%I;:K2;H[Z2K+>JP:%?DWBBB*RCN1A4V)8UXZ.LW3.*BB1CB=,
MH\\E#A'^X9%[M;^>XG>^C7:LID<R`=J;B:]OA0=]+C$XQ+)\=':VHL9*EHO:
M01DDUJ5``/Y_CK.+U:N.8(*NY@(1Q6@9HQX5U>)8+0(,&XIBW9!$*(&C_M&_
MQ%[$_C["=H<`'`=))<723FZ$LG[LON]S<0]?CN[U^>E3861MA9F&+]D$V^WM
M'M[?ALIMI\J4TU>4FGR,5'04A5*P^A(<[=2'AGD!%.HJ*4:)G1:GCHY=JHS9
M';)*&*F*1""0HB`<`/1DO+])FG2>59GK5E9@S5[[C6IKZZ++C<?+"MN\$+0)
M3:K(I5:=MJTH*>E-/'=9K[^1CIA]"0SV7AP.$1*O(MBYDHL%/_H$<_704=,0
M/]?B.7GI%);N&)X(99%MY*[TW-M?M^L5ZT[CYZ5DM+6:9+B2.-IX_P!#%%+)
M44.QJ56HZ&E.FFCJEU-].-+,]K%;>61BD"#*PNX&,<3K-$O=VI-9=9L>0;IE
M[QX`B@`'(_CTK%=7D-J;**:5+0_TU=@G7_36E=(R8O&SW2WMQ!#)=KV=HT+C
MY!RNX?QTZ2J]=19.(U&`@THYVX*\=L$XA@FR<NTUDG";MPT(@""SDBZ!#@<Q
M1,!R%,`\@'1C=W9E$S2RF0+0'<=P%".C5K2AI3M32@LK58C;K%$(&:I78-I-
M002.Q((K7XT.HW?F.\3F4LYY'7VHUGB4KA:YJ&BXS*N,$W36/G)AQ7F2<9$W
M"FG>J-X^3D3PZ"35\P.LDLH#9)5#Y#B=/K6/V_><\-P_&_\`QO+Y&BLC*6@G
M-2D8;]4;@`D"M"&%1WK2G7&?W(_;]F^7Y(\XX:BSY`QJLUL*"1R.@D0DT8T_
M4IH1W%:FD:.6U3VB@I%S$2^N&=V,DS5,BZ:*8COYU$5"B)>!.A7U43@(AZ&*
M<Q1#U`1#K95MY&X)=6XNHLQCC`W8B9>OY=_X@'6'KGQOSZUNWLI<-DA<(:$>
MP_?\0"/X:)+#/BJWWS<X9A7M>;=4X=T<@&LV4P0QM"-4C]O<X42LIF\^Z2('
M/(-6+@X\>A>?3J(\B\]^+^-V\AN,K#<R%/ICMP97W=?YA]*U[#<1J9<8^WSR
MMRB91:8N:V@8[6DN![:`=/1Z$]Z]`=2']*_`CB##4I#9$V:LK7.M\BW#:1CZ
M0Q9.(_$<%)-50707=M'@$F;PLW5(0Q?O?MF(F+^IH?T'K)7D;[F^0<KM6Q/%
MXFQN+==KR$UN)5^!(%$7X`;C_JULWQA]J/&^+31Y;F$J9/*QL&2-5VP1D?\`
M4":RFOQ"K\CWU(%0;(MD$6R":2+=NF1%!!%,J2*""10(DBBDF!2)))$*!2E*
M`%*```!QUE]BS.9&-7))J>IZ]^O_`!UK81QJ@C4!8@``HZ``"@``[`>@U=$G
M<`@(CP/T#TX_G[]%9:K125/Q'?1QT(IV`U]%#M*!>>>`XY_A_#HP_,ZX*TZF
@IU7H:[I=#0TNAH:70T-+H:&ET-#2Z&AI=#0TNAH:_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
